Table of Contents Table of Contents
Previous Page  177 / 198 Next Page
Information
Show Menu
Previous Page 177 / 198 Next Page
Page Background

For the year ended 31 May 2016

175

BLUE LABEL INTEGRATED ANNUAL REPORT 2016

NOTES TO THE COMPANY ANNUAL FINANCIAL STATEMENTS

continued

2016

R’000

2015

R’000

15. Operating profit

The following items have been charged/(credited), in arriving at

operating profit/(loss):

Acquisition-related costs

21 639

1 971

Audit fees – other

134

128

Audit fees – services as auditors

7 355

3 962

Consulting fees

6 882

9 909

Dividend received**

(9 821)

—

Foreign exchange profit**

(26 049)

(10 559)

Contingent purchase price release (refer to note 2)

(30 924)

(923)

Impairment of loans and investments*

2 496

23 484

Reversal of impairment of loans and investments

(157 914)

#

(53 927)***

Insurance

899

890

Legal fees

198

914

Management fees received**

(109 499)

(108 272)

Operating lease rentals – premises

(897)

(1 298)

Rental paid

13 507

12 358

Rental recovery

(14 404)

(13 656)

Overseas travel

2 166

2 266

Loss/(profit) on disposal of property, plant and equipment**

4

(1)

(Profit)/loss on disposal of subsidiary

(900)

334

* An impairment loss of R2.5 million (2015: R23.5 million) was recognised in the current year relating to the impairment of a

related party loan in line with our stated accounting policies (refer to note 21). The related-party loan has been fully impaired

due to the continuing trading losses in these entities which are not considered to be immediately recoverable.

** Included in other income. Refer to note 21.

*** The reversal of impairment relates to the loan to Gold Label Investments Proprietary Limited (Gold Label). The reversal arose due

to Gold Label repaying a portion of the loan previously impaired.

#

The reversal of impairment relates to the investment in Cellfind SA Proprietary Limited of R141.8 million and the investment in

Datacel Direct Proprietary Limited of R16.1 million. The reversal arose due to the impairment indicators of these assets no longer

being applicable. Value-in-use calculations were performed on these assets and their provisions for impairment reversed. Refer

to note 4.1 of the Group financial statements.